Ekso Bionics Holdings Inc 2025年度报告

If securities are registered pursuant to Section 12(b) of the Act, indicate by check mark whether the financial statements of the registrant included in the filingreflect the correction of an error to previously issued financial statements.☐ Indicate by check mark whether any of those error corrections are restatements that required a recovery analysis of incentive-based compensation received byany of the registrant’s executive officers during the relevant recovery period pursuant to §240.10D-1(b).☐ The aggregate market value of the registrant's common stock held by non-affiliates of the registrant was $8,158,292based on the last sale price for such stockon June 30, 2025, the last business day of the registrant's most recently completed second fiscal quarter. Table of Contents EXPLANATORY NOTE This Amendment No. 1 on Form 10-K/A (this "Amendment") amends Ekso Bionics Holdings, Inc.'s (the "Company")Annual Report on Form 10-K for thefiscal year ended December 31, 2025, which was filed with the Securities and Exchange Commission (the "SEC") on February 23, 2026(the "Original Filing"). This Amendment is being filed solely for the purposes of providing the information required in Part III of the Company’s Annual Report on Form 10-K forthe fiscal year ended December 31, 2025because a definitive proxy statement containing such information will not be filed within 120 days after the end of suchfiscal year. Pursuant to the rules of the SEC, we have also included as exhibits currently dated certifications required under Section 302 of The Sarbanes-OxleyAct of 2002. Because no financial statements are contained within this Amendment, we are not including certifications pursuant to Section 906 of The Sarbanes-Oxley Act of 2002. We are amending and refiling Part IV, Item 15 to reflect the inclusion of those certifications, along with any changes to Part IV that occurred Unless otherwise noted herein, including in Item 12 of this Amendment, this Amendment does not reflect events occurring after the date of the OriginalFiling and does not modify or update disclosures contained in the Original Filing, including, without limitation, the financial statements. Accordingly, this PART III Item 10.DIRECTORS, EXECUTIVE OFFICERS AND CORPORATE GOVERNANCE Background of Directors and Executive Officers Set forth below are the name and age as of March 18, 2026of each of our current directors and executive officers, the positions held by each current directorand executive officer with us, his or her principal occupation and business experience during the last five years, and the year of the commencement of his or herterm as a director or executive officer. Additionally, for each current director standing for re-election, included below is information regarding the specific Directors are elected to serve until the next annual meeting of stockholders and until their successors are elected and qualified. Executive officers areappointed by our Board of Directors and serve at its pleasure. There is no family relationship between any of our directors or executive officers. No person wasselected as a director or officer pursuant to any arrangement or understanding. Directors Scott G. Davisis our Chief Executive Officer and has served as our Chief Executive Officer and a member of our Board of Directors since December 2022and previously served as our President and Chief Operating Officer from January 2022 through December 2022 after first serving as Executive Vice President ofStrategy and Corporate Development from April 2021 through January 2022. Mr. Davis has more than two decades of worldwide leadership success in fastgrowing high-tech companies. Prior to joining the Company, from December 2018 through March 2021, Mr. Davis served as Chief Executive Officer ofGlobalmatix, Inc., a disruptive Internet of Things connected telematics solution provider, and from January 2017 through December 2018, he served as SeniorVice President of Strategy for GetWireless, LLC, a telecommunications equipment provider. From 2015 through 2020, he provided C-level consulting servicesassisting on scalability, process improvement, business development, M&A support and go-to-market strategy as President of SGD Executive Services LLC. Mary Ann Cloydis a member of our Board of Directors and serves as the Chair of the Audit Committee and as a member of the Nominating and GovernanceCommittee of our Board of Directors. She has served on our Board of Directors since January 2021. From 1990 until her retirement in June 2015, Ms. Cloyd wasa partner with PricewaterhouseCoopers LLP, a global accounting and consulting firm. During her 25 years as a partner at PwC, Ms. Cloyd served in multipleleadership positions. For example, from 2012 until her retirement, Ms. Cloyd led PwC’s Center for Board Governance. Ms. Cloyd is a retired Certified PublicAccountant. Ms. Cloyd served as a director of Bellerophon Therapeutics, Inc. (Nasdaq: BLPH), a publicly traded clinica